[
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Dips As Trump Eyes This Fed Pick; Defense Stock Tests Entry (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index rose Monday. Tesla neared a buy point while President Trump edged closer to a Fed chair pick.",
    "url": "https://finnhub.io/api/news?id=327de47e8f6440da94ed9b1453777fbadb7b7c23005c5f4eb6b6b6a50ec3014e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765824104,
      "headline": "Stock Market Today: Dow Dips As Trump Eyes This Fed Pick; Defense Stock Tests Entry (Live Coverage)",
      "id": 137795183,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Stock Market Today: The Dow Jones index rose Monday. Tesla neared a buy point while President Trump edged closer to a Fed chair pick.",
      "url": "https://finnhub.io/api/news?id=327de47e8f6440da94ed9b1453777fbadb7b7c23005c5f4eb6b6b6a50ec3014e"
    }
  },
  {
    "ts": null,
    "headline": "J&J gains label expansion approval for Akeega in mCSPC",
    "summary": "Akeega’s indicated usage now spans across mCSPC and mCRPC, widening the drug’s future market potential.",
    "url": "https://finnhub.io/api/news?id=e97113f476e1daf2b7929619e9612de4378c5f851802658bc16d5f6ff94824ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765822223,
      "headline": "J&J gains label expansion approval for Akeega in mCSPC",
      "id": 137795315,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Akeega’s indicated usage now spans across mCSPC and mCRPC, widening the drug’s future market potential.",
      "url": "https://finnhub.io/api/news?id=e97113f476e1daf2b7929619e9612de4378c5f851802658bc16d5f6ff94824ff"
    }
  },
  {
    "ts": null,
    "headline": "B of A Securities Maintains Johnson & Johnson (JNJ) Neutral Recommendation",
    "summary": "B of A Securities Maintains Johnson & Johnson (JNJ) Neutral Recommendation",
    "url": "https://finnhub.io/api/news?id=274a785eed8a63959a3cb259c9debc0dd5b6acf63bd85dfb5ffd4e906630100b",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765821517,
      "headline": "B of A Securities Maintains Johnson & Johnson (JNJ) Neutral Recommendation",
      "id": 137794933,
      "image": "",
      "related": "JNJ",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=274a785eed8a63959a3cb259c9debc0dd5b6acf63bd85dfb5ffd4e906630100b"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Remains Stable With Modest Growth Potential, BofA Says",
    "summary": "Johnson & Johnson (JNJ) remains a stable, relatively low-risk stock, though its upside appears limit",
    "url": "https://finnhub.io/api/news?id=341f23f56e73aa6dad40a8dc368fa154f6bdb2af996f150b8d2243ca00f0dc4b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765817386,
      "headline": "Johnson & Johnson Remains Stable With Modest Growth Potential, BofA Says",
      "id": 137795316,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) remains a stable, relatively low-risk stock, though its upside appears limit",
      "url": "https://finnhub.io/api/news?id=341f23f56e73aa6dad40a8dc368fa154f6bdb2af996f150b8d2243ca00f0dc4b"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Industrial Average's top-performing stocks of 2025",
    "summary": "Ahead of the new year, Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at some of the Dow Jones Industrial Average's (^DJI) best performers in 2025: Caterpillar (CAT), Goldman Sachs (GS), Johnson & Johnson (JNJ), and IBM (IBM). To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
    "url": "https://finnhub.io/api/news?id=7d14e244ac58983b05bc4f57063adce070331e5fdd3d0fd656d785b66d5a19ec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765814400,
      "headline": "Dow Jones Industrial Average's top-performing stocks of 2025",
      "id": 137795317,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Ahead of the new year, Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at some of the Dow Jones Industrial Average's (^DJI) best performers in 2025: Caterpillar (CAT), Goldman Sachs (GS), Johnson & Johnson (JNJ), and IBM (IBM). To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
      "url": "https://finnhub.io/api/news?id=7d14e244ac58983b05bc4f57063adce070331e5fdd3d0fd656d785b66d5a19ec"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves J&J's Akeega for Expanded Use in Prostate Cancer",
    "summary": "JNJ secures FDA approval to expand Akeega into earlier-stage prostate cancer, backed by strong phase III data and a first-of-its-kind precision combo.",
    "url": "https://finnhub.io/api/news?id=016ec6656259e23215aa0832c2e669b7f3e3bb5d4de810e6322f567d24914d58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765813740,
      "headline": "FDA Approves J&J's Akeega for Expanded Use in Prostate Cancer",
      "id": 137795318,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ secures FDA approval to expand Akeega into earlier-stage prostate cancer, backed by strong phase III data and a first-of-its-kind precision combo.",
      "url": "https://finnhub.io/api/news?id=016ec6656259e23215aa0832c2e669b7f3e3bb5d4de810e6322f567d24914d58"
    }
  },
  {
    "ts": null,
    "headline": "AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD",
    "summary": "AC Immune receives a \"Buy\" rating, driven by positive phase 2 VacSYn trial results for ACI-7104.056 in early Parkinson's Disease. Click to read why ACIU is a Buy.",
    "url": "https://finnhub.io/api/news?id=d86daf2e6abfe57cef65f29f94eb1dc07cad0146e40c3223a5bb07c1a6ccecf8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765810259,
      "headline": "AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD",
      "id": 137796206,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2242672740/image_2242672740.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "AC Immune receives a \"Buy\" rating, driven by positive phase 2 VacSYn trial results for ACI-7104.056 in early Parkinson's Disease. Click to read why ACIU is a Buy.",
      "url": "https://finnhub.io/api/news?id=d86daf2e6abfe57cef65f29f94eb1dc07cad0146e40c3223a5bb07c1a6ccecf8"
    }
  },
  {
    "ts": null,
    "headline": "MRK Gets Positive CHMP Opinion for Expanded Use of Winrevair in PAH",
    "summary": "Merck secures a positive CHMP opinion to expand Winrevair's PAH use, potentially broadening treatment to adult patients across WHO FC II-IV.",
    "url": "https://finnhub.io/api/news?id=9b8dfb9692d98bb0f8e473627fd4622ed1717583afe48fe2b0c16eb7379c474a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765810200,
      "headline": "MRK Gets Positive CHMP Opinion for Expanded Use of Winrevair in PAH",
      "id": 137795319,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Merck secures a positive CHMP opinion to expand Winrevair's PAH use, potentially broadening treatment to adult patients across WHO FC II-IV.",
      "url": "https://finnhub.io/api/news?id=9b8dfb9692d98bb0f8e473627fd4622ed1717583afe48fe2b0c16eb7379c474a"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True?",
    "summary": "Based on the average brokerage recommendation (ABR), Johnson & Johnson (JNJ) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
    "url": "https://finnhub.io/api/news?id=c223b4a3010e4d1822eafbb5c983711981f57236e0fae39459a53a30a1af791a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765809003,
      "headline": "Johnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True?",
      "id": 137795320,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Based on the average brokerage recommendation (ABR), Johnson & Johnson (JNJ) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
      "url": "https://finnhub.io/api/news?id=c223b4a3010e4d1822eafbb5c983711981f57236e0fae39459a53a30a1af791a"
    }
  },
  {
    "ts": null,
    "headline": "Take the Zacks Approach to Beat the Markets: Liquidia, Western Digital & Johnson & Johnson in Focus",
    "summary": "Liquidia shares have surged 43.9% since an October upgrade, as Zacks highlights stock wins and portfolio results despite a volatile market.",
    "url": "https://finnhub.io/api/news?id=d2fe2ac5d62c0836e6093c1c0ba6727281375d8883652cdea40206127b4bbbe7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765807560,
      "headline": "Take the Zacks Approach to Beat the Markets: Liquidia, Western Digital & Johnson & Johnson in Focus",
      "id": 137792757,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Liquidia shares have surged 43.9% since an October upgrade, as Zacks highlights stock wins and portfolio results despite a volatile market.",
      "url": "https://finnhub.io/api/news?id=d2fe2ac5d62c0836e6093c1c0ba6727281375d8883652cdea40206127b4bbbe7"
    }
  },
  {
    "ts": null,
    "headline": "Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors",
    "summary": "Link Cell Therapies (\"Link\"), an oncology cell therapy company, today announced its official launch from stealth with a $60 million Series A financing that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc. , with participation from founding investors Samsara BioCapital and Sheatree Capital, as well as Wing Venture Capital and other new strategic and financial investors.",
    "url": "https://finnhub.io/api/news?id=151c93ba9b46d6ccbb682f5c83c7cd7619b0f4fde4518373b6b7ec637376ef46",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765805400,
      "headline": "Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors",
      "id": 137792120,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Link Cell Therapies (\"Link\"), an oncology cell therapy company, today announced its official launch from stealth with a $60 million Series A financing that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc. , with participation from founding investors Samsara BioCapital and Sheatree Capital, as well as Wing Venture Capital and other new strategic and financial investors.",
      "url": "https://finnhub.io/api/news?id=151c93ba9b46d6ccbb682f5c83c7cd7619b0f4fde4518373b6b7ec637376ef46"
    }
  },
  {
    "ts": null,
    "headline": "The Best Dividend Stocks for Retirement Portfolios in 2026",
    "summary": "Retirement portfolios need growing income that outpaces inflation and safety that lets you sleep at night. The best retirement dividend stocks build reliable income streams that compound for decades. These companies raise dividends through recessions, market crashes, and business disruptions. We ranked them by dividend growth consistency, payout sustainability, and business resilience heading into 2026. ... The Best Dividend Stocks for Retirement Portfolios in 2026",
    "url": "https://finnhub.io/api/news?id=13e23502495419c1cbfbfc606c521facda3dcb121348c0dc553d7e24c64bb86c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765802566,
      "headline": "The Best Dividend Stocks for Retirement Portfolios in 2026",
      "id": 137792112,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Retirement portfolios need growing income that outpaces inflation and safety that lets you sleep at night. The best retirement dividend stocks build reliable income streams that compound for decades. These companies raise dividends through recessions, market crashes, and business disruptions. We ranked them by dividend growth consistency, payout sustainability, and business resilience heading into 2026. ... The Best Dividend Stocks for Retirement Portfolios in 2026",
      "url": "https://finnhub.io/api/news?id=13e23502495419c1cbfbfc606c521facda3dcb121348c0dc553d7e24c64bb86c"
    }
  }
]